Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2022-05-11 Regulatory Filings
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 11, 2022, reporting the financial results for the first quarter ended March 31, 2022. It specifically states that the financial results are provided via a press release attached as Exhibit 99.1. The document itself is short (3703 characters) and primarily serves to announce the release of the earnings press release rather than containing detailed financial statements or analysis. According to the 'Menu vs Meal' rule, such a document that announces or attaches a report but does not contain the full report itself should be classified as a Regulatory Filing (RNS) rather than an Earnings Release (ER) or Interim Report (IR). Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2022-05-11 English
CIDARA THERAPEUTICS, INC. FORM 10-Q
Interim / Quarterly Report Q1 2022
2022-05-11 English
DEFINITIVE ADDITIONAL MATERIALS
Remuneration Information Classification · 95% confidence The document is identified as 'DEFA14A' and contains terms such as 'Definitive Additional Materials' and 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934.' The DEFA14A form is a definitive additional proxy solicitation material filed under the Securities Exchange Act. This type of filing is related to remuneration or governance matters typically associated with proxy statements. Given the form type and content, the document fits the category of Remuneration Information filings, which include proxy statements detailing compensation and related materials. The document length is short and does not contain full financial reports or earnings data, so it is not an Annual Report or Earnings Release. Therefore, the correct classification is 'DEF 14A' with high confidence.
2022-04-29 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2022-04-29 English
FORM 4
Director's Dealing
2022-04-04 English
FORM 4
Director's Dealing
2022-04-04 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.